Brokerages expect Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) to report ($0.24) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Oramed Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.27). Oramed Pharmaceuticals posted earnings per share of ($0.20) during the same quarter last year, which would indicate a negative year-over-year growth rate of 20%. The firm is expected to announce its next quarterly earnings report on Monday, April 22nd.
According to Zacks, analysts expect that Oramed Pharmaceuticals will report full year earnings of ($0.99) per share for the current fiscal year, with EPS estimates ranging from ($1.05) to ($0.92). For the next fiscal year, analysts forecast that the company will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.00) to ($0.98). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Oramed Pharmaceuticals.
Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Oramed Pharmaceuticals in a report on Monday.
Shares of Oramed Pharmaceuticals stock opened at $3.97 on Friday. The company has a market capitalization of $71.78 million, a PE ratio of -4.62 and a beta of 1.17. Oramed Pharmaceuticals has a one year low of $2.78 and a one year high of $8.59.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Read More: Why is cost of goods sold important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.